2018
Serial Assessment of Coronary Flow Reserve by Rubidium-82 Positron Emission Tomography Predicts Mortality in Heart Transplant Recipients
Feher A, Srivastava A, Quail MA, Boutagy NE, Khanna P, Wilson L, Miller EJ, Liu YH, Lee F, Sinusas AJ. Serial Assessment of Coronary Flow Reserve by Rubidium-82 Positron Emission Tomography Predicts Mortality in Heart Transplant Recipients. JACC Cardiovascular Imaging 2018, 13: 109-120. PMID: 30343093, PMCID: PMC6461525, DOI: 10.1016/j.jcmg.2018.08.025.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery DiseaseFemaleFractional Flow Reserve, MyocardialHeart TransplantationHumansMaleMiddle AgedMyocardial Perfusion ImagingPositron-Emission TomographyPredictive Value of TestsProspective StudiesRadiopharmaceuticalsReproducibility of ResultsRubidium RadioisotopesTime FactorsTreatment OutcomeConceptsPositron emission tomographyLong-term prognostic valueSerial assessmentPET-2Pet-1Cause mortalityHT patientsPrognostic valueHigh CFRLow CFRRb positron-emission tomographyEmission tomographyRb-82 positron emission tomographyRubidium-82 positron emission tomographyPET imagingHeart transplantation patientsHistory of HTCardiac allograft vasculopathyHeart transplant recipientsLong-term mortalitySingle-center studyMultivariate Cox regressionCoronary flow reserveAllograft vasculopathyHT recipients
2017
Joint SNMMI–ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring
Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, Birnie DH, Chen ES, Cooper LT, Tung RH, White ES, Borges-Neto S, Di Carli MF, Gropler RJ, Ruddy TD, Schindler TH, Blankstein R, GROUP N, Bateman T, Cerqueira M, Dilsizian V, Heller G, Moller D, Osborne M, Sadeghi M, Soman P. Joint SNMMI–ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. Journal Of Nuclear Medicine 2017, 58: 1341-1353. PMID: 28765228, PMCID: PMC6944184, DOI: 10.2967/jnumed.117.196287.Peer-Reviewed Original Research
2016
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairmentThe response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis
Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. Journal Of Nuclear Cardiology 2016, 24: 413-424. PMID: 27457527, DOI: 10.1007/s12350-016-0490-7.Peer-Reviewed Original ResearchConceptsFDG PET/CTPET/CTFDG uptakeCardiac sarcoidosisFDG PET/CT studiesPET/CT studiesImmunosuppressive treatmentCardiac inflammationPartial responseComplete resolutionImproved outcomesSUV thresholdImmunosuppressionFDG responseCT studiesPatientsCTSarcoidosisFurther studiesQuantitative changesUptakeResponseInflammationSUVmaxCMV